<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p117" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_117{left:130px;bottom:1195px;letter-spacing:0.2px;}
#t2_117{left:796px;bottom:1195px;letter-spacing:0.13px;}
#t3_117{left:141px;bottom:1104px;letter-spacing:-0.01px;}
#t4_117{left:250px;bottom:1104px;letter-spacing:-0.01px;}
#t5_117{left:143px;bottom:1044px;letter-spacing:-0.29px;}
#t6_117{left:250px;bottom:1064px;letter-spacing:-0.01px;}
#t7_117{left:248px;bottom:1009px;letter-spacing:-0.04px;}
#t8_117{left:238px;bottom:949px;letter-spacing:-0.01px;}
#t9_117{left:238px;bottom:929px;letter-spacing:-0.01px;}
#ta_117{left:238px;bottom:910px;letter-spacing:-0.01px;}
#tb_117{left:238px;bottom:890px;letter-spacing:-0.01px;}
#tc_117{left:238px;bottom:842px;letter-spacing:-0.01px;}
#td_117{left:238px;bottom:823px;letter-spacing:-0.01px;}
#te_117{left:238px;bottom:804px;letter-spacing:-0.01px;}
#tf_117{left:238px;bottom:784px;letter-spacing:-0.01px;}
#tg_117{left:238px;bottom:765px;letter-spacing:-0.01px;}
#th_117{left:238px;bottom:745px;letter-spacing:-0.01px;}
#ti_117{left:238px;bottom:726px;letter-spacing:-0.01px;}
#tj_117{left:238px;bottom:706px;letter-spacing:-0.01px;}
#tk_117{left:238px;bottom:687px;letter-spacing:-0.01px;}
#tl_117{left:238px;bottom:667px;letter-spacing:-0.01px;}
#tm_117{left:238px;bottom:648px;letter-spacing:-0.01px;}
#tn_117{left:238px;bottom:561px;letter-spacing:-0.01px;}
#to_117{left:238px;bottom:542px;letter-spacing:-0.01px;}
#tp_117{left:238px;bottom:522px;letter-spacing:-0.01px;}
#tq_117{left:238px;bottom:503px;letter-spacing:-0.01px;}
#tr_117{left:238px;bottom:483px;letter-spacing:-0.01px;}
#ts_117{left:238px;bottom:445px;letter-spacing:-0.01px;}
#tt_117{left:238px;bottom:425px;letter-spacing:-0.01px;}
#tu_117{left:238px;bottom:406px;letter-spacing:-0.01px;}
#tv_117{left:238px;bottom:386px;letter-spacing:-0.01px;}
#tw_117{left:238px;bottom:367px;letter-spacing:-0.01px;}
#tx_117{left:238px;bottom:347px;letter-spacing:-0.01px;}
#ty_117{left:238px;bottom:299px;letter-spacing:-0.01px;}
#tz_117{left:238px;bottom:280px;letter-spacing:-0.01px;}
#t10_117{left:238px;bottom:260px;letter-spacing:-0.01px;}
#t11_117{left:238px;bottom:241px;letter-spacing:-0.01px;}
#t12_117{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_117{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_117{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_117{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_117{font-size:28px;font-family:NotoSans-Regular_7j-;color:#000;}
.s4_117{font-size:10px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts117" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg117Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg117" style="-webkit-user-select: none;"><object width="908" height="1286" data="117/117.svg" type="image/svg+xml" id="pdf117" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_117" class="t s0_117">7.11. Palliative therapy </span><span id="t2_117" class="t s1_117">117 </span>
<span id="t3_117" class="t s2_117">7.81. </span><span id="t4_117" class="t s2_117">Consensus-based recommendation </span>
<span id="t5_117" class="t s3_117">EEC </span>
<span id="t6_117" class="t s2_117">In second-line therapy, therapy with a PD-1 inhibitor should be offered. </span>
<span id="t7_117" class="t s4_117">Strong consensus: 100% </span>
<span id="t8_117" class="t s2_117">The development of systemic therapy is currently very dynamic, with more than 30 ongoing </span>
<span id="t9_117" class="t s2_117">phase 2 and phase 3 studies. The most important effective substances are cisplatin, 5-FU, </span>
<span id="ta_117" class="t s2_117">methotrexate, docetaxel, paclitaxel, cetuximab and antibodies against PD1 or PD-L1. Signal </span>
<span id="tb_117" class="t s2_117">transduction inhibitors (afatinib and burlalisib) are also effective, but are not approved. </span>
<span id="tc_117" class="t s2_117">There are no specific studies on laryngeal carcinoma, only collective studies for patients with </span>
<span id="td_117" class="t s2_117">squamous cell carcinoma of all head and neck locations except the nasopharynx. With </span>
<span id="te_117" class="t s2_117">monotherapy of cytotoxic substances, response rates are below 20%. Combination therapy can </span>
<span id="tf_117" class="t s2_117">increase the response rate to up to 30%, but does not improve the median survival time. With </span>
<span id="tg_117" class="t s2_117">the combination of platinum salts, 5-FU and cetuximab, a response rate of 36% was achieved </span>
<span id="th_117" class="t s2_117">(38% when using cisplatin). The median progression-free time was improved from 3.3 to 5.6 </span>
<span id="ti_117" class="t s2_117">months by adding cetuximab to chemotherapy, and the median survival rate from 7.4 to 10.1 </span>
<span id="tj_117" class="t s2_117">months [411]. However, the 2-year survival rate remained below 20%. Based on the results of </span>
<span id="tk_117" class="t s2_117">this study, palliative chemotherapy with platinum (preferably cisplatin) and 5-FU in combination </span>
<span id="tl_117" class="t s2_117">with cetuximab is the current standard in first-line therapy. A combination of platinum, </span>
<span id="tm_117" class="t s2_117">docetaxel and cetuximab achieves similar results; results of randomized trials are pending. </span>
<span id="tn_117" class="t s2_117">Monotherapy with the PD1 antibody nivolumab was investigated in a randomized study against </span>
<span id="to_117" class="t s2_117">a free comparator therapy (methotrexate, docetaxel or cetuximab monotherapy). Patients with </span>
<span id="tp_117" class="t s2_117">platinum-refractory squamous cell carcinoma were included, mostly as second-line therapy </span>
<span id="tq_117" class="t s2_117">after cisplatin, 5-FU and cetuximab, but also after other prior therapies, or directly after </span>
<span id="tr_117" class="t s2_117">radiochemotherapy. The response rate in this mixed study was </span>
<span id="ts_117" class="t s2_117">Patient population 13.3% versus 5.8% with comparator therapy, the median progression-free </span>
<span id="tt_117" class="t s2_117">time 2.0 vs. 2.3 months and the median survival time 7.5 vs. 5.1 months [410]. The decisive </span>
<span id="tu_117" class="t s2_117">factors for the approval of nivolumab were the increased 1-year survival rate from 16.6% to </span>
<span id="tv_117" class="t s2_117">36.0% with the indication of a plateau and the significantly improved overall survival (OS) </span>
<span id="tw_117" class="t s2_117">hazard ratio (0.70, p=0.01). Similar results were achieved in two studies with the antibody </span>
<span id="tx_117" class="t s2_117">pembrolizumab, which is also directed against PD1 [412, 413]. </span>
<span id="ty_117" class="t s2_117">Current studies are testing additional antibodies against PD1 and PD-L1 as well as various </span>
<span id="tz_117" class="t s2_117">combinations of cytotoxic substances, cetuximab, PD1/PD-L1 antibodies and numerous other </span>
<span id="t10_117" class="t s2_117">immunomodulatory molecules with the aim of improving the remission rate and long-term </span>
<span id="t11_117" class="t s2_117">outcomes without a significant increase in toxicity. </span>
<span id="t12_117" class="t s0_117">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
